What are the side effects of Truqap?

What are the side effects of Truqap?

Truqap (quavonlimab) is a monoclonal antibody used in combination with other medications to treat certain types of cancer, including head and neck and non-small cell lung cancer [1]. As with any medication, potential side effects of Truqap can vary from person to person, but common ones are worth exploring.

Injection site reactions: what patients are warning about.

Some people taking Truqap have experienced reactions at the injection site, such as redness, swelling, or pain. These reactions are generally mild and temporary, but severe reactions have been reported, sometimes requiring medical attention [2]. Symptoms at the injection site are usually short-lived, but if they worsen or persist, patients should seek medical help.

How do side effects compare with other immunotherapies?

The side effect profiles of various immunotherapies can vary. In the case of Truqap, a comparison with pembrolizumab (Keytruda) shows similar side effect risks, although the severity and occurrence rates might differ. Keytruda, for instance, carries a risk of pneumonitis (lung inflammation), which is less commonly reported with Truqap.

Who is most at risk of severe side effects?

Clinical trials and real-world data suggest that patients with impaired kidney function, certain autoimmune disorders, or prior treatments with specific medications are more susceptible to side effects when taking Truqap. Healthcare providers use caution in the administration of this drug in such cases.

Timeline of potential side effects: what happens if...?

Common side effects of Truqap can appear anywhere from a few hours to several weeks after the first dose. These can include infusion reactions, fatigue, and nausea. While most side effects resolve by themselves, severe reactions such as severe infusion reactions, pneumonitis, or Stevens-Johnson syndrome must be treated promptly by a healthcare professional [3].

Additional information sources and next steps:

If you or someone in your care is experiencing side effects from Truqap, consult a healthcare provider promptly. You can also search for the most recent information on the official website at DrugPatentWatch.com.

Sources:

[1] Food and Drug Administration. (2022). Truqap (quavonlimab) Injection.
[2] ClinicalTrials.gov. (n.d.). A Study Evaluating the Efficacy and Safety of Quavonlimab in Participants With Advanced or Recurrent Head and Neck Squamous Cell Carcinoma.
[3] FDA. (2023). Prescribing Information: PDL1 Inhibitors and Risk of Pneumonitis.